OnKure, Inc
OnKure, Inc is a Boulder-based company specializing in the discovery and development of precision medicines for cancer patients. With a team of industry leaders and a proven track record of success, they are dedicated to advancing the next generation of oncology therapies. Their broad pipeline includes potentially best-in-class tumor-agnostic treatments, including a Phase 2 HDAC inhibitor for multiple cancer types.
OnKure recently achieved a significant milestone with the U.S. FDA clearance of their Mutant Selective PI3Ka inhibitor, OKI-219, enabling Phase 1 initiation. The company's commitment to precision medicine and their continuous efforts in research and development make them a key player in the field of oncology therapeutics.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.

